Highlighting Promising TRK Inhibitors for the Treatment of Thyroid Cancer
David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.
David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics and associate vice president of clinical research at The University of Texas MD Anderson Cancer Center, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib (Vitrakvi).
Overall, a significant amount of patients respond to larotrectinib and the responses appear very durable, Hong says. The hope with LOXO-195, another TRK inhibitor, is to see more of these significant responses and durability in these patients. Like many other small molecule agents, the next steps include determining the mechanisms of resistance and if other drugs can be developed that are less toxic.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
